Biotech In 2018: Will Repatriated Cash Fuel A Feeding Frenzy?
(WorldNews Health)

After a slow 2016, many thought mergers and acquisitions activity in the biotech sector would come roaring back to life in 2017. As it turned out, 2017 was also uneventful. With the exception of Johnson & Johnson´s (JNJ) January move to make an all-cash buyout of Actelion (OTCPK:ALIOY) for $30 billion and the acquisition of Kite Pharma (KITE) by Gilead Sciences (GILD) in August for $11.9 billion, there has been little in the way of excitement on the M&A front. In 2018, the sleepy biotech M&A market should finally wake up. After months of uncertainty and wrangling, it looks like a tax bill will pass that will see huge tax discounts on the trillions of dollars stored by American...